0 Commentarios
0 Acciones
26 Views
0 Vista previa
Buscar
Descubre nuevas personas, crear nuevas conexiones y hacer nuevos amigos
-
Please log in to like, share and comment!
-
MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval Creating a New Rare-Disease Revenue Stream?MEK inhibitors targeting neurofibromatosis type 1-associated plexiform neurofibromas — the oral allosteric MEK1/2 inhibitors selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringWorks Therapeutics) approved for pediatric and adult NF1 patients with symptomatic, inoperable tumors — represent the fastest-growing indication segment in the MEK inhibitor market, with the...0 Commentarios 0 Acciones 190 Views 0 Vista previa